Literature DB >> 33445713

The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention.

Kerstin Menck1,2, Saskia Heinrichs1,2, Cornelia Baden1,2, Annalen Bleckmann1,2,3.   

Abstract

The WNT pathway is one of the major signaling cascades frequently deregulated in human cancer. While research had initially focused on signal transduction centered on β-catenin as a key effector activating a pro-tumorigenic transcriptional response, nowadays it is known that WNT ligands can also induce a multitude of β-catenin-independent cellular pathways. Traditionally, these comprise WNT/planar cell polarity (PCP) and WNT/Ca2+ signaling. In addition, signaling via the receptor tyrosine kinase-like orphan receptors (RORs) has gained increasing attention in cancer research due to their overexpression in a multitude of tumor entities. Active WNT/ROR signaling has been linked to processes driving tumor development and progression, such as cell proliferation, survival, invasion, or therapy resistance. In adult tissue, the RORs are largely absent, which has spiked the interest in them for targeted cancer therapy. Promising results in preclinical and initial clinical studies are beginning to unravel the great potential of such treatment approaches. In this review, we summarize seminal findings on the structure and expression of the RORs in cancer, their downstream signaling, and its output in regard to tumor cell function. Furthermore, we present the current clinical anti-ROR treatment strategies and discuss the state-of-the-art, as well as the challenges of the different approaches.

Entities:  

Keywords:  CAR T cells; ROR1; ROR2; WNT signaling; cancer; immunotherapy; non-canonical; targeted therapy

Year:  2021        PMID: 33445713      PMCID: PMC7828172          DOI: 10.3390/cells10010142

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  192 in total

1.  Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development.

Authors:  T Matsuda; M Nomi; M Ikeya; S Kani; I Oishi; T Terashima; S Takada; Y Minami
Journal:  Mech Dev       Date:  2001-07       Impact factor: 1.882

2.  HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Authors:  Fernanda Faião-Flores; Michael F Emmons; Michael A Durante; Fumi Kinose; Biswarup Saha; Bin Fang; John M Koomen; Srikumar P Chellappan; Silvya Stuchi Maria-Engler; Uwe Rix; Jonathan D Licht; J William Harbour; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

3.  The Wnt receptor CRD domain is also found in MuSK and related orphan receptor tyrosine kinases.

Authors:  P Masiakowski; G D Yancopoulos
Journal:  Curr Biol       Date:  1998-06-04       Impact factor: 10.834

4.  Src and Fyn define a new signaling cascade activated by canonical and non-canonical Wnt ligands and required for gene transcription and cell invasion.

Authors:  Aida Villarroel; Beatriz Del Valle-Pérez; Guillem Fuertes; Josué Curto; Neus Ontiveros; Antonio Garcia de Herreros; Mireia Duñach
Journal:  Cell Mol Life Sci       Date:  2019-07-16       Impact factor: 9.261

5.  Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Authors:  Hanna Karvonen; David Chiron; Wilhelmiina Niininen; Sara Ek; Mats Jerkeman; Elaheh Moradi; Matti Nykter; Caroline A Heckman; Olli Kallioniemi; Astrid Murumägi; Daniela Ungureanu
Journal:  Blood Adv       Date:  2017-11-09

6.  Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

Authors:  U Klein; Y Tu; G A Stolovitzky; M Mattioli; G Cattoretti; H Husson; A Freedman; G Inghirami; L Cro; L Baldini; A Neri; A Califano; R Dalla-Favera
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

7.  Ectopic repression of receptor tyrosine kinase-like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial-mesenchymal transition.

Authors:  Ying Xu; Yan-Hui Ma; Ying-Xin Pang; Zhe Zhao; Jing-Jing Lu; Hong-Luan Mao; Pei-Shu Liu
Journal:  Tumour Biol       Date:  2017-05

8.  Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.

Authors:  Wen Gao; Michael Wang; Li Wang; Haibo Lu; Shuhong Wu; Bingbing Dai; Zhishuo Ou; Liang Zhang; John V Heymach; Kathryn A Gold; John Minna; Jack A Roth; Wayne L Hofstetter; Stephen G Swisher; Bingliang Fang
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

Review 9.  Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics.

Authors:  Muhammad Haseeb; Rameez Hassan Pirzada; Qurat Ul Ain; Sangdun Choi
Journal:  Cells       Date:  2019-11-03       Impact factor: 6.600

10.  Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis.

Authors:  Md Kamrul Hasan; George F Widhopf; Suping Zhang; Sharon M Lam; Zhouxin Shen; Steven P Briggs; Barbara A Parker; Thomas J Kipps
Journal:  NPJ Breast Cancer       Date:  2019-10-25
View more
  17 in total

1.  ROR1-targeting switchable CAR-T cells for cancer therapy.

Authors:  Haiyong Peng; Thomas Nerreter; Katrin Mestermann; Jakob Wachter; Jing Chang; Michael Hudecek; Christoph Rader
Journal:  Oncogene       Date:  2022-07-20       Impact factor: 8.756

2.  Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen.

Authors:  Peyman Bemani; Setareh Moazen; Elham Nadimi; Foroogh Nejatollahi
Journal:  Rep Biochem Mol Biol       Date:  2022-07

Review 3.  Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.

Authors:  Mahshid Deldar Abad Paskeh; Maliheh Entezari; Sepideh Mirzaei; Amirhossein Zabolian; Hossein Saleki; Mohamad Javad Naghdi; Sina Sabet; Mohammad Amin Khoshbakht; Mehrdad Hashemi; Kiavash Hushmandi; Gautam Sethi; Ali Zarrabi; Alan Prem Kumar; Shing Cheng Tan; Marios Papadakis; Athanasios Alexiou; Md Asiful Islam; Ebrahim Mostafavi; Milad Ashrafizadeh
Journal:  J Hematol Oncol       Date:  2022-06-28       Impact factor: 23.168

Review 4.  TLR/WNT: A Novel Relationship in Immunomodulation of Lung Cancer.

Authors:  Aina Martín-Medina; Noemi Cerón-Pisa; Esther Martinez-Font; Hanaa Shafiek; Antònia Obrador-Hevia; Jaume Sauleda; Amanda Iglesias
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

5.  WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer.

Authors:  Claudia Binder; Annalen Bleckmann; Kerstin Menck; Saskia Heinrichs; Darius Wlochowitz; Maren Sitte; Helen Noeding; Andreas Janshoff; Hannes Treiber; Torben Ruhwedel; Bawarjan Schatlo; Christian von der Brelie; Stefan Wiemann; Tobias Pukrop; Tim Beißbarth
Journal:  J Exp Clin Cancer Res       Date:  2021-12-15

6.  De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.

Authors:  Loélia Babin; Alice Darchen; Elie Robert; Zakia Aid; Rosalie Borry; Claire Soudais; Marion Piganeau; Anne De Cian; Carine Giovannangeli; Olivia Bawa; Charlotte Rigaud; Jean-Yves Scoazec; Lucile Couronné; Layla Veleanu; Agata Cieslak; Vahid Asnafi; David Sibon; Laurence Lamant; Fabienne Meggetto; Thomas Mercher; Erika Brunet
Journal:  Mol Cancer       Date:  2022-03-04       Impact factor: 27.401

Review 7.  Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling.

Authors:  Kinjal Shah; Julhash U Kazi
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

8.  Transcriptomic Biomarker Signatures for Discrimination of Oral Cancer Surgical Margins.

Authors:  Simon A Fox; Michael Vacher; Camile S Farah
Journal:  Biomolecules       Date:  2022-03-17

9.  Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening.

Authors:  Luis Córdova-Bahena; Axel A Sánchez-Álvarez; Angel J Ruiz-Moreno; Marco A Velasco-Velázquez
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22

10.  Prognostic Role of Receptor Tyrosine Kinase-Like Orphan Receptors in Intestinal-Type Gastric Cancer.

Authors:  Rajeev Nema; Priti Patel; Ashok Kumar
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.